Numab
Founded 2011 · 75 employees on LinkedIn · 1 known investors
Find your way into Numab
133 people in our graph share verified history with the Numab team — schools, employers, funds. One of them is your warm intro.
Martin Scherrerunlockedknows David Urech · together at University of Zurich (overlapped)
%20(4).avif)
×11knows the team · via University of Zurich
Numab develops multispecific antibody-based therapeutics using its proprietary λ-Cap and MATCH discovery and engineering platforms, aiming to improve on first-generation antibody therapies in potency, stability, effect duration, and safety. It maintains its own drug pipeline targeting clinically validated pathways and works with pharma and biotech partners on discovery and development.
Founders & leadership
Numab was founded in 2011 by David Urech.
DU
Investors · 1
Frequently asked questions
- What does Numab do?
- Numab develops multispecific antibody-based therapeutics using its proprietary λ-Cap and MATCH discovery and engineering platforms, aiming to improve on first-generation antibody therapies in potency, stability, effect duration, and safety. It maintains its own drug pipeline targeting clinically validated pathways and works with pharma and biotech partners on discovery and development.
- Who founded Numab?
- Numab was founded by David Urech in 2011.
- Who are Numab's investors?
- Numab's investors include Eisai Innovation, Inc..